Liječnički vjesnik, Vol. 139 No. 1-2, 2017.
Stručni rad
GUIDELINES FOR DIAGNOSIS AND TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME
Njetočka Gredelj Šimec
Gordana Kaić
Anita Škrtić
Zoran Šiftar
Ružica Lasan-Trčić
Toni Valković
Biljana Jelić Puškarić
Inga Mandac Rogulj
Viktor Zatezalo
Damir Nemet
Slobodanka Ostojić Kolonić
Sažetak
Myelodysplastic syndrome Working Group of the Croatian Cooperative Group for Hematologic Diseases
(CROHEM), Referral center of the Ministry of Health of the Republic of Croatia for diagnostics and treatment of MDS, as
well as the Croatian Society for Haematology of the Croatian Medical Association have made Croatian guidelines for
diagnosis and treatment of myelodysplastic syndrome (MDS). MDS is a heterogeneous group of clonal hematopoietic stem
cell disorders characterized by ineffective hematopoiesis, dysplasia, cytopenia and risk of transformation to acute myeloid
leukemia (AML). Diagnosis is based on morphological characteristics of hematopoietic cells supplemented with the cytogenetic
analysis and bone marrow fl ow cytometry. Due to great differences in the natural course of the disease, i.e. time
to progression to AML and the expected time of survival several scoring systems have been developed to determine the
disease risk. The treatment of patients with MDS is based on the risk factors of the disease as well as the individual risk of
treatment.
Ključne riječi
Myelodysplastic syndrome – classifi cation, diagnosis, genetics, pathology, therapy; Hematopoietic stem cells – pathology; Bone marrow – pathology; Bone marrow cells – pathology; Leukemia, myeloid, acute – pathology; Cytological techniques – methods; Immunophenotyping; Cytogenetic analysis; Prognosis; Survival analysis; Risk assessment – analysis; Practice guidelines as topic; Croatia
Hrčak ID:
178434
URI
Datum izdavanja:
23.3.2017.
Posjeta: 3.299 *